NeuroThera Labs Granted U.S. Patent for MRSA-Treating Cannabinoid Tech

OG article by CEN Staff

February 5, 2026

NeuroThera Labs, a clinical-stage pharmaceutical company developing treatments for central nervous system disorders, has secured a U.S. patent for its innovative technology combining antimicrobials with cannabinoids to combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). The patent covers compositions and methods that potentiate existing antibiotics, enhancing their efficacy against Gram-positive pathogens where monotherapy fails. It integrates well-known antibiotics with cannabinoids such as THC and CBD, and sometimes N-acylethanolamines like palmitoylethanolamide (PEA). Preclinical studies show synergistic effects that restore antibiotic activity, offering an "antimicrobial-sparing" approach that reduces the need for new drugs, limits resistance development, and minimizes side effects like organ toxicity or gastrointestinal issues. By building on antibiotics with established long-term safety data, the platform promises effective, safe, and cost-efficient solutions for resistant infections. This U.S. patent strengthens NeuroThera's intellectual property, joining prior grants in other regions, and positions the technology as a novel tool in addressing antimicrobial resistance through cannabinoid integration.